The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XVII.e

Pneumocystis jiroveci pneumonia

Publications

Harigai M, Koike R, Miyasaka N, Pneumocystis Pneumonia under Anti-Tumor Necrosis Factor Therapy (PAT) Study Group

Pneumocystis pneumonia associated with infliximab in Japan.

The New England journal of medicine. 2007;357(18):1874-6

Kaur N, Mahl TC

Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.

Digestive diseases and sciences. 2007;52(6):1481-4

Imaizumi K, Sugishita M, Usui M, Kawabe T, Hashimoto N, Hasegawa Y

Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.

Internal medicine (Tokyo, Japan). 2006;45(10):685-8

Velayos FS, Sandborn WJ

Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.

Inflammatory bowel diseases. 2004;10(5):657-60

Tai TL, O'Rourke KP, McWeeney M, Burke CM, Sheehan K, Barry M

Pneumocystis carinii pneumonia following a second infusion of infliximab.

Rheumatology (Oxford, England). 2002;41(8):951-2